Clinical trial
A Post Approval Commitment Study for Pharmacokinetic Analysis and Providing Expanded Access to Bortezomib (Velcade) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma in Taiwan
NCT01801436 is registered in ClinicalTrials.gov with Johnson & Johnson Taiwan Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Post Approval Commitment Study for Pharmacokinetic Analysis and Providing Expanded Access to Bortezomib (Velcade) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma in Taiwan
- Lead sponsor
- Johnson & Johnson Taiwan Ltd
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2006
- Completion date
- April 30, 2008
- Enrollment
- 14 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.